Immunome, Inc. (NASDAQ:IMNM) Insider Robert Lechleider Buys 15,805 Shares of Stock

Immunome, Inc. (NASDAQ:IMNM) insider Robert Lechleider purchased 15,805 shares of Immunome stock in a transaction dated Thursday, November 21st. The stock was bought at an average cost of $9.48 per share, with a total value of $149,831.40. Following the completion of the transaction, the insider now directly owns 15,805 shares of the company’s stock, valued at $149,831.40. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Immunome Stock Performance

Shares of IMNM stock opened at $11.15 on Tuesday. The stock’s 50 day simple moving average is $12.49 and its 200 day simple moving average is $13.55. Immunome, Inc. has a twelve month low of $6.93 and a twelve month high of $30.96. The company has a market capitalization of $695.98 million, a price-to-earnings ratio of -1.37 and a beta of 1.82.

Wall Street Analysts Forecast Growth

IMNM has been the subject of a number of research reports. Stephens started coverage on shares of Immunome in a research note on Friday, November 8th. They set an “overweight” rating and a $30.00 target price for the company. Wedbush restated an “outperform” rating and issued a $33.00 target price on shares of Immunome in a research note on Friday, October 25th. Finally, Piper Sandler cut their price target on Immunome from $23.00 to $21.00 and set an “overweight” rating for the company in a research note on Thursday, November 14th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat, Immunome has a consensus rating of “Buy” and an average price target of $28.83.

Hedge Funds Weigh In On Immunome

Institutional investors have recently modified their holdings of the company. Price T Rowe Associates Inc. MD raised its holdings in Immunome by 113.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,245,673 shares of the company’s stock worth $55,425,000 after acquiring an additional 1,194,451 shares during the period. Marshall Wace LLP grew its position in shares of Immunome by 228.5% in the second quarter. Marshall Wace LLP now owns 1,713,325 shares of the company’s stock valued at $20,731,000 after purchasing an additional 1,191,774 shares during the last quarter. Farallon Capital Management LLC bought a new position in shares of Immunome in the first quarter worth about $14,660,000. Janus Henderson Group PLC lifted its position in shares of Immunome by 10.3% during the 3rd quarter. Janus Henderson Group PLC now owns 3,488,121 shares of the company’s stock worth $50,971,000 after purchasing an additional 324,614 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its stake in Immunome by 217.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 442,477 shares of the company’s stock valued at $6,469,000 after purchasing an additional 302,916 shares during the period. Institutional investors own 44.58% of the company’s stock.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.